Search results
Results from the WOW.Com Content Network
Acetazolamide is an inhibitor of carbonic anhydrase.It is used for glaucoma, epilepsy (rarely), idiopathic intracranial hypertension, and altitude sickness. For the reduction of intraocular pressure (IOP), acetazolamide inactivates carbonic anhydrase and interferes with the sodium pump, which decreases aqueous humor formation and thus lowers IOP.
Apraclonidine is indicated for the short-term adjunctive treatment of glaucoma for patients on maximally tolerated medical therapy who require additional reduction of IOP. These patients, who are treated with apraclonidine to delay surgery, should have frequent follow-up examinations and treatment should be discontinued if the intraocular ...
Netarsudil, sold under the brand name Rhopressa among others, is a medication for the treatment of glaucoma. [1] [2] [3] In the United States, in December 2017, the Food and Drug Administration (FDA) approved a 0.02% ophthalmic solution for the lowering of elevated intraocular pressure in people with open-angle glaucoma or ocular hypertension.
BrightFocus Foundation is a nonprofit organization based in Clarksburg, Maryland.BrightFocus funds research in an effort to discover cures for Alzheimer's disease, macular degeneration and glaucoma, and provides information and free English and Spanish resources to increase awareness about these diseases.
Glaucoma medication is divided into groups based on chemical structure and pharmacologic action. The goal of currently available glaucoma therapy is to preserve visual function by lowering intraocular pressure (IOP) in patients that have an increased intraocular pressure.
Collaborative Initial Glaucoma Treatment Study: This study compared the effects of medical treatment to early filtration surgery in newly diagnosed open-angle glaucoma. It found that increased eye pressure was significantly decreased in both the medically and surgically treated groups, with the surgery group having a larger decrease.
A mother has revealed her baby was born with extreme glaucoma, cataracts, no irises and has developed a “bubble-like” protrusion on her eyeball.. Aspen Schuelke was born in March 2022 and ...
Kowa Company was issued a US patent (No. 8,193,193, entitled ‘‘Agent for prevention or treatment of glaucoma’’) on June 5, 2012 for the use of ripasudil in patients with glaucoma. [9] As of June 25th, 2013, Glanatec is a registered U.S. federal trademark attributed to Kowa.